These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 38440725)

  • 1. Insights into the heterogeneity of iNKT cells: tissue-resident and circulating subsets shaped by local microenvironmental cues.
    Cui G; Abe S; Kato R; Ikuta K
    Front Immunol; 2024; 15():1349184. PubMed ID: 38440725
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tissue-specific functions of invariant natural killer T cells.
    Crosby CM; Kronenberg M
    Nat Rev Immunol; 2018 Sep; 18(9):559-574. PubMed ID: 29967365
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of liver-specific CD24
    Li X; Jin C; Chen Q; Zheng X; Xie D; Wu Q; Wang L; Bai S; Zhang H; Bai L
    J Leukoc Biol; 2022 Jun; 111(6):1199-1210. PubMed ID: 34730251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Strategy of lipid recognition by invariant natural killer T cells: 'one for all and all for one'.
    Mallevaey T; Selvanantham T
    Immunology; 2012 Jul; 136(3):273-82. PubMed ID: 22671023
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functions of CD1d-Restricted Invariant Natural Killer T Cells in Antimicrobial Immunity and Potential Applications for Infection Control.
    Kinjo Y; Takatsuka S; Kitano N; Kawakubo S; Abe M; Ueno K; Miyazaki Y
    Front Immunol; 2018; 9():1266. PubMed ID: 29928278
    [TBL] [Abstract][Full Text] [Related]  

  • 6. License to Kill: When iNKT Cells Are Granted the Use of Lethal Cytotoxicity.
    Díaz-Basabe A; Strati F; Facciotti F
    Int J Mol Sci; 2020 May; 21(11):. PubMed ID: 32486268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A circulating subset of iNKT cells mediates antitumor and antiviral immunity.
    Cui G; Shimba A; Jin J; Ogawa T; Muramoto Y; Miyachi H; Abe S; Asahi T; Tani-Ichi S; Dijkstra JM; Iwamoto Y; Kryukov K; Zhu Y; Takami D; Hara T; Kitano S; Xu Y; Morita H; Zhang M; Zreka L; Miyata K; Kanaya T; Okumura S; Ito T; Hatano E; Takahashi Y; Watarai H; Oike Y; Imanishi T; Ohno H; Ohteki T; Minato N; Kubo M; Holländer GA; Ueno H; Noda T; Shiroguchi K; Ikuta K
    Sci Immunol; 2022 Oct; 7(76):eabj8760. PubMed ID: 36269840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of NKT14m and Low Dose IL-12 Promotes Invariant Natural Killer T Cell IFN-γ Production and Tumor Control.
    Guan P; Schaub R; Nichols KE; Das R
    Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32708464
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Invariant natural killer T cells: innate-like T cells with potent immunomodulatory activities.
    Wu L; Gabriel CL; Parekh VV; Van Kaer L
    Tissue Antigens; 2009 Jun; 73(6):535-45. PubMed ID: 19392798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The ins and outs of type I iNKT cell development.
    Shissler SC; Webb TJ
    Mol Immunol; 2019 Jan; 105():116-130. PubMed ID: 30502719
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel Approaches to Exploiting Invariant NKT Cells in Cancer Immunotherapy.
    Wolf BJ; Choi JE; Exley MA
    Front Immunol; 2018; 9():384. PubMed ID: 29559971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hiding lipid presentation: viral interference with CD1d-restricted invariant natural killer T (iNKT) cell activation.
    Horst D; Geerdink RJ; Gram AM; Stoppelenburg AJ; Ressing ME
    Viruses; 2012 Oct; 4(10):2379-99. PubMed ID: 23202469
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Positive & Negative Roles of Innate Effector Cells in Controlling Cancer Progression.
    Stolk D; van der Vliet HJ; de Gruijl TD; van Kooyk Y; Exley MA
    Front Immunol; 2018; 9():1990. PubMed ID: 30298063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distinct and overlapping effector functions of expanded human CD4+, CD8α+ and CD4-CD8α- invariant natural killer T cells.
    O'Reilly V; Zeng SG; Bricard G; Atzberger A; Hogan AE; Jackson J; Feighery C; Porcelli SA; Doherty DG
    PLoS One; 2011; 6(12):e28648. PubMed ID: 22174854
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Harnessing the Power of Invariant Natural Killer T Cells in Cancer Immunotherapy.
    Bedard M; Salio M; Cerundolo V
    Front Immunol; 2017; 8():1829. PubMed ID: 29326711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Invariant natural killer T cells: bridging innate and adaptive immunity.
    Van Kaer L; Parekh VV; Wu L
    Cell Tissue Res; 2011 Jan; 343(1):43-55. PubMed ID: 20734065
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How Lipid-Specific T Cells Become Effectors: The Differentiation of iNKT Subsets.
    Wang H; Hogquist KA
    Front Immunol; 2018; 9():1450. PubMed ID: 29997620
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Subset of CD8αβ+ Invariant NKT Cells in a Humanized Mouse Model.
    Wen X; Kim S; Xiong R; Li M; Lawrenczyk A; Huang X; Chen SY; Rao P; Besra GS; Dellabona P; Casorati G; Porcelli SA; Akbari O; Exley MA; Yuan W
    J Immunol; 2015 Aug; 195(4):1459-69. PubMed ID: 26157173
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New Genetically Manipulated Mice Provide Insights Into the Development and Physiological Functions of Invariant Natural Killer T Cells.
    Ren Y; Sekine-Kondo E; Tateyama M; Kasetthat T; Wongratanacheewin S; Watarai H
    Front Immunol; 2018; 9():1294. PubMed ID: 29963043
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploiting CD1-restricted T cells for clinical benefit.
    Exley MA; Dellabona P; Casorati G
    Mol Immunol; 2021 Apr; 132():126-131. PubMed ID: 33582549
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.